Background. We have observed a number of patients who fail to develop coccidioidal complement fixing (CF) antibody (immunoglobulin [IgG]) after the initiation of early antifungal therapy. Although this is the first description of this phenomenon in mycology, a precedent for the abrogation of the immune response has been observed in other conditions, including primary syphilis and primary Lyme disease.
Coccidioidomycosis (also known as San Joaquin fever or Valley Fever) is caused by infection with the dimorphic fungus Coccidioides (Coccidioides immitis and Coccidioides posadasii). In recent years the incidence of infection within endemic areas has increased, and the Centers for Disease Control and Prevention have mandated reporting of coccidioidomycosis cases within endemic regions in a concerted effort to define the true incidence and prevalence of infection [1, 2] . Diagnosis is established by recovery of Coccidioides spp. from an affected site, histopathologic demonstration of the organism (proven infection), or a compatible clinical picture combined with mycologic or serologic evidence (probable infection) [3] . The high sensitivity, specificity, and noninvasive nature of serologic testing have allowed this method to remain the mainstay of diagnosis.
In most cases, signs and symptoms of infection with Coccidioides spp. begin 7-28 days after the inhalation of arthroconidia. The development of an immunoglobulin (IgM) antibody response follows over the next 7-21 days, followed by the development of an IgG response within 2-3 months of exposure [4] . However, one of the authors (D. P.) has observed a number of patients who produced IgM but failed to develop an IgG response when this would be expected. This appeared to be associated with early fluconazole therapy. It was speculated that fluconazole may inhibit the formation of chitinase-the antigen reactive with coccidioidal IgG antibody. Similarly, others have reported a lack of antibody production after early treatment in both primary syphilis [5] and primary Lyme disease [6] . Additionally, early therapy to diminish antibody formation forms the basis for antibiotics in the primary prevention of rheumatic fever during streptococcal pharyngitis [7] . The requirement for the continued presence of antigen to develop an IgG response is the likely basis for these findings.
METHODS
A retrospective case-control study was designed to test whether a higher incidence of early antifungal therapy (receipt of antifungal therapy ,14 days after symptom onset) was seen in patients who failed to develop coccidioidal complement fixing (CF) antibodies (IgG) than in patients who either did not receive antifungal therapy or received antifungal therapy $14 days after symptom onset. This study was approved by the Institutional Review Board of the University of California, Davis.
Cases were identified by a review of all patients noted to be persistently positive for IgM antibodies (.90 days) from the Coccidioidomycosis Serology Laboratory database between 2003 and 2010. Patients were excluded from evaluation if they developed IgG antibody at any time or if insufficient clinical information was available for chart abstraction. For the control cohort, we included consecutive patients with a known diagnosis of coccidioidomycosis who were evaluated between 2009 and 2010 at the University of California, Davis Medical Center. Patients were excluded from either group if they did not meet previously established criteria for the diagnosis of proven or probable coccidioidomycosis [3] .
Chart abstraction was performed to identify demographic variables, including age, sex, and ethnicity; date of symptom onset; antifungal agents prescribed; type of coccidioidal infection; and any comorbid conditions that may have accounted for a failure to manifest an appropriate immunologic response. Data analysis was performed using R software (version 2.10). Differences in demographic characteristics were evaluated using Student's t test for continuous variables and Fisher's exact test for categorical variables. Differences were considered statistically significant at P , .05.
Spherule-endospore (SE) cultures were prepared as described elsewhere using the C. posadasii strain Silveira [8] . Cultures were grown in the absence of fluconazole (Pfizer) (growth control) and with increasing concentrations of fluconazole, ranging from 0.5 to 128 lg/mL. Culture filtrates were collected at 72 hours. Serologic testing for the presence of antigens reactive with IgM and IgG antibodies by immunodiffusion was performed as described elsewhere, using previously heated antigen to detect IgM antibody reactivity and unheated antigen to detect the antigen (chitinase Cts1) reactive with IgG [4] .
Reverse-transcription polymerase chain reaction analysis of Cts1 messenger RNA (mRNA) expression was performed as described elsewhere [8] , except the following primers were used for chitinase (Cts1) mRNA expression: Cts1 forward, 5#-GTGGTC ATAACCCGCAAGAT-3#; Cts1 reverse, 5#-CGGTGAAGCAA-TAGTGAGCA-3#. Chitinase enzyme activity was measured in solution using a colorimetric method with the chromogenic substrate, p-nitrophenyl b-D-N,N#,N##-triacetylchitotriose (SigmaAldrich), as described elsewhere [8] . Table 1 shows the characteristics of the 17 patients who were persistently positive for IgM antibodies without developing an IgG response (case patients). Nine male and 8 female patients, ranging in age from 11 to 70 years (mean, 44.1 years), made up the case group. Sixty-four consecutive patients who developed IgG antibodies served as controls. Five patients had proven . The duration of follow-up available ranged from 112 to 1998 days (mean, 602 days). Development of IgG antibodies was significantly associated with initiation of antifungal therapy within 14 days of the appearance of symptoms (P , .001). None of the 15 patients who received antifungal therapy within 14 days of symptoms developed IgG antibody (4 of these 15 patients were culture positive). Of the 66 patients who received antifungal therapy (controls and 2 case patients) after 14 days, all but 2 developed the IgG antibody (1 of the controls was culture positive and receiving chronic prednisone therapy).
RESULTS
We additionally found no association between development of IgG antibody and patient ethnicity (P 5 .343), nor was the development of IgG antibodies associated with the type of coccidioidal infection (P 5 .121). However, in almost all cases, the infection was a primary pulmonary infection (75 of 81 patients) with cavitary pneumonia, disseminated disease, or meningitis in the remaining 6 patients.
As mentioned elsewhere, it had been speculated that the growth of C. posadasii in the SE phase in the presence of fluconazole might inhibit the production of chitinase (Cts1), the antigen responsible for IgG seropositivity. Figure 1 shows the seroreactivity of control serum known to be positive for both coccidioidal precipitin (IgM) and CF (IgG) antibodies. The serum is shown to be reactive to both previously heated (60°C) coccidioidin (heated spherulin antigen [hSpAg]), indicating the presence of IgM antibody (the ''inner'' line), and unheated antigen, indicating the presence of IgG antibody. A reaction consistent with IgM was also observed against all Coccidioides preparations, including those grown in the absence of fluconazole (controls in Figures 1A and 1C ) and those grown under escalating fluconazole concentrations. A reaction consistent with IgG was observed in filtrates of cultures grown in the absence of fluconazole, and questionable reactions were observed in filtrates from very low concentrations of fluconazole. The presence of IgM was confirmed after dissolution of lines of identity with the addition of dithiothreitol. Figure 2 illustrates the reactivity of control serum known to be positive only for CF (IgG) antibodies with culture filtrates. The serum is shown to be reactive only to CF antigen and growth controls. The failure of these lines to dissolve after the addition of dithiothreitol confirms their identity as IgG.
Coccidioides SE phase Cts1 mRNA expression declined inversely with fluconazole exposure, whereas ribosomal RNA expression remained unchanged in the presence of escalating fluconazole concentrations (Figure 3 ). These findings suggest that the observed decline in Cts1 mRNA is not secondary to organism-wide decrease in protein synthesis or fungal death, but rather that the reduction may be limited to genes such as CTS1. These results are further substantiated by the reduction in endochitinase activity when a Coccidioides SE phase isolate is exposed to increasing fluconazole concentrations (Figure 4 ).
DISCUSSION
Infection with Coccidioides spp. is associated with the development of T-and B-cell immune responses [9] . However, in Although this phenomenon appears uncommon, it may complicate serodiagnosis and epidemiologic studies examining the incidence and prevalence of this reportable disease.
A precedent for the abrogation of an IgG antibody response after early treatment has been described after antimicrobial therapy in primary syphilis and primary Lyme disease [6, 10] . It is thought that the rapid bactericidal effects of antimicrobial therapy reduce the antigenemia to a degree that immunologic recognition is not well established and T and B cells thus do not interact effectively. Antimicrobial therapy may thus preclude the full development of the IgG response but not the IgM antibody response [10] , as was observed in our case-control study reported here.
The major antigen for coccidioidal IgM appears to be a glycopeptide, and the major antigen for coccidioidal complement fixation IgG is chitinase Cts1 [11] . In the presence of antifungal therapy, the amount of exposed chitinase may be reduced at a critical early stage in the immune response before a sustained B-cell response has developed. Our in vitro investigation has confirmed antigenic differences in filtrates of cultures grown in the presence of fluconazole, as observed by the immunodiffusion results and total Cts1 mRNA expression. Similarly, recent work indicates that another triazole, voriconazole, suppresses expression of the chitinase genes CHT1, CHT2, and CHT3 in Candida albicans [12] .
It is unlikely that IgG antibodies are protective against the development of coccidioidal infection in view of both relapses and progression of disease despite high complement fixation (IgG) titers. Although in the past the control of coccidioidomycosis was primarily thought to be T-cell-dependent, more recent evidence has suggested a role of B cells in protecting against Coccidioides spp. In fact, vaccination against coccidioidomycosis is not fully protective in B-cell-deficient mice [13] .
A recent observational study found that patients who received antifungals experienced a higher complication rate (including the development of disseminated disease) after withdrawal of antifungal therapy [14] . In line with our data, this observation could be attributed to diminished humoral immunity after antifungal therapy, but the interval between symptoms and receipt of antifungal therapy was not discussed in the other study. Additionally, a lack of randomization in that study limits the ability to draw inferences on the decision to treat or not to treat primary pulmonary coccidioidomycosis. The clinical implications of a failure to develop IgG antibodies thus remain uncertain. Patients treated within 14 days of symptom onset may have been more symptomatic than those who were not. However, in the absence of prospective trials and assignment of symptom scores at the time of initial clinical presentation, this variable cannot be definitively evaluated.
In conclusion, we have observed a statistically significant abrogation of the IgG antibody response in some patients with invasive coccidioidomycosis when early antifungal therapy (,14 days after symptom onset) is initiated. Although this phenomenon is uncommon, it may complicate serodiagnosis and the epidemiology regarding this reportable disease. Furthermore, the potential clinical impact of this phenomenon will need to be analyzed in future studies. It remains to be determined whether abrogation of an IgG antibody response reflects a significant lessening of disease burden after early antifungal therapy, or merely a reduction in antibody response, and clinical follow-up of the case patients is needed. 
